Related Experiment Video
Updated: May 12, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
B-Raf and the inhibitors: from bench to bedside
Tiangui Huang1, Michael Karsy, Jian Zhuge
1Department of Pathology, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA.
Journal of Hematology & Oncology
|April 27, 2013
Summary
This review covers B-Raf signaling in cancer, focusing on the V600E mutation and targeted therapies like vemurafenib. It also discusses therapeutic resistance mechanisms and strategies to overcome them.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- B-Raf protein is crucial in the MAPK signaling pathway.
- The V600E mutation leads to constitutive B-Raf activation, driving cancer pathogenesis.
- Targeting B-Raf is a key strategy in cancer therapy.
Purpose of the Study:
- To review B-Raf signaling mechanisms.
- To discuss B-Raf mutation detection methods.
- To explore B-Raf inhibitor therapies and resistance mechanisms.
Main Methods:
- Literature review of B-Raf signaling and inhibitors.
- Analysis of current treatment strategies.
- Discussion of resistance mechanisms and overcoming strategies.
Main Results:
- Several small molecule B-Raf inhibitors have been evaluated (e.g., vemurafenib, dabrafenib).
- Therapeutic resistance to B-Raf inhibitors is a significant clinical challenge.
- Various mechanisms of resistance have been identified.
Conclusions:
- Understanding B-Raf signaling is vital for cancer treatment.
- Targeted therapies show promise but face resistance.
- Further research is needed to overcome resistance and improve patient outcomes.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...